
-
Cabaletta Bio NasdaqGS:CABA Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Location: 2929 Arch Street, Philadelphia, PA, 19104, United States | Website: https://www.cabalettabio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-8.147M
Cash
131.8M
Avg Qtr Burn
-23.76M
Short % of Float
12.72%
Insider Ownership
2.98%
Institutional Own.
72.40%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rese-cel (formerly CABA-201) Details Myasthenia gravis | Phase 1/2 Data readout | |
Rese-cel (formerly CABA-201) Details Pemphigus Vulgaris | Phase 1/2 Data readout | |
Phase 1/2 Data readout | ||
Rese-cel (formerly CABA-201) Details Immune-mediated necrotizing myopathy, Anti-synthetase syndrome, Idiopathic inflammatory myopathy / myositis, Dermatomyositis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1/2 Data readout | |
Rese-cel (formerly CABA-201) Details Systemic lupus erythematosus, Lupus nephritis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1/2 Data readout | |
MuSK-CAART Details Myasthenia gravis, Autoimmune disease | Phase 1 Data readout | |
DSG3-CAART Details Mucosal Pemphigus Vulgaris | Phase 1 Update |